

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
14 February 2002 (14.02.2002)

PCT

(10) International Publication Number  
WO 02/11785 A2(51) International Patent Classification<sup>7</sup>: A61M

(21) International Application Number: PCT/US01/24405

(22) International Filing Date: 3 August 2001 (03.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/222,759 3 August 2000 (03.08.2000) US

(71) Applicant (for all designated States except US): UNIVERSITY OF UTAH [US/US]; Technology Transfer Office, Suite 110, 615 Arapen Drive, Salt Lake City, UT 84108 (US).

(72) Inventor: LI, Dean, Y.; 1416 S. Wasatch, Salt Lake City, UT 84108 (US).

(74) Agent: BUCHANAN, J., Matthew; Brinks Hofer Gilson &amp; Lione, P.O. Box 10395, Chicago, IL 60610 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).**Published:**

- without international search report and to be republished upon receipt of that report
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MANIPULATION OF ARTERIAL-VENOUS IDENTITY

(57) Abstract: Methods and compositions for manipulating the arterial-venous identity of endothelial cells are provided. The methods comprise introducing an arterial molecular program into endothelial cells of a vein section such that the endothelial cells can remodel to form arterial endothelial cells. The arterial molecular program can comprise one or more polynucleotides encoding various genes that are associated with arterial development and/or differentiation from veins. Expression vectors comprising the genes can be used to introduce the molecular program into the cells. A method of treating a patient having an obstructed blood vessel is also provided.

## MANIPULATION OF ARTERIAL-VEINOUS IDENTITY

### FIELD OF THE INVENTION

**[0001]** The present invention relates to methods and compositions for manipulating the arterial-venous identity of endothelial cells. More particularly, the invention relates to methods of inducing arterial morphology in a vein by transferring an appropriate polynucleotide into endothelial cells of the vein. Further, the invention relates to methods of treating a patient having an obstructed blood vessel.

### BACKGROUND OF THE INVENTION

**[0002]** Obstruction of blood vessels diminishes the ability of the vessel to deliver blood to downstream organs, which impacts the long-term health of the organ and its host. These obstructive disorders are generally referred to as arteriosclerosis. Atherosclerosis, a specific form of arteriosclerosis, primarily affects the aorta and the coronary arteries.

**[0003]** Replacement of the obstructed vessel with a graft of some type is the mainstay of surgical treatment for obstructive vascular disease. A common example of this type of procedure is coronary artery bypass grafting (CABG). This procedure is aimed at alleviating poor blood perfusion of the heart that results from obstructed coronary arteries, and represents the great majority of vessel replacement procedures in humans. In a CABG procedure, a surgeon removes an obstructed segment of the coronary artery and replaces it with a graft.

**[0004]** Choice of graft in any vessel replacement procedure is affected by numerous factors, including rejection by the host immune system, vessel size, and ease of harvesting and handling. For CABG procedures, autologous vessels, particularly the saphenous vein, are predominantly used as the replacement vessel. The saphenous vein, which ascends along the inner side of the leg, is relatively easy to harvest and has a suitable cross-sectional size relative to the coronary arteries. Furthermore, as an

autologous vessel, tissue rejection concerns are eliminated. Considering these advantages, it is not surprising that replacement of an obstructed coronary artery section with a section of an autologous saphenous vein has become a common surgical technique for CABG procedures.

**[0005]** Despite these advantages, significant drawbacks remain. For example, recent estimates indicate that as many as 30% of patients who require a CABG procedure do not have veins suitable for grafting. (See Bourassa, *Curr. Opin. Cardiol.* 9: 685-691 (1994)). Furthermore, approximately 50% of venous bypass grafts are no longer patent, i.e., structurally intact, ten years after grafting, (See Edwards, et al., *Surg. Gynecol. & Obstet.* 122: 37-42 (1996)). The loss of patency of the graft has serious consequences: at a minimum, it can create a need for an additional surgical procedure and, as a worst case, can lead to heart damage and death. Considering these limitations and the many benefits of bypass grafting, there is tremendous interest in improving the patency of vascular grafts.

**[0006]** The use of a vein segment in place of an artery segment probably contributes to the loss of patency in grafts. Arteries have various structural features that are not present in veins. For example, while veins are typically composed of a single layer of endothelium surrounded by a relatively low number of vascular smooth muscle cells, the endothelium of arteries are surrounded by alternating rings of elastic lamellae and vascular smooth muscle cells. These structural differences allow arteries to accommodate different physiological conditions than veins. For example, arteries are typically under higher hemodynamic stress (70-105 mm Hg) than veins (0-8 mm Hg).

**[0007]** Because of these structural features, the use of arteries as grafts has been explored. Indeed, a relatively high percentage of internal mammary artery (IMA) grafts remains intact for years after the grafting procedure. (See Barner, et al., *J. Thorac. Cardiovasc. Surg.* 90:668-75 (1985)). Thus, the use of arteries appears to have advantages over the use of vascular grafts. Unfortunately, arteries are frequently difficult to

harvest. Various technical difficulties are associated with preparation of the IMA and other arteries, such as the gastroepiploic and splenic arteries, placing these vessels in disfavor as replacement grafts.

**[0008]** An ideal graft for replacement of an obstructed section of an artery could be a vessel that combines the benefits of veins, such as ease of harvesting, with those of arteries, such as the above-mentioned structural features.

**[0009]** During embryonic development, endothelial tubes have the capacity to develop into both veins and arteries. The endothelial tubes acquire a specific identity as either an artery or vein prior to the development of the structural features that distinguish the two types of vessels. Molecular programs, comprising various genes and gene products, regulate the identity of these vessels as either arterial or vascular tissue. However, the mere replacement of a vein under arterial hemodynamic conditions does not lead to the transformation of the vein into an artery.

#### SUMMARY OF THE INVENTION

**[0010]** The present invention provides methods of inducing arterial morphology in a vein. The method comprises changing the arterial-venous identity of endothelial cells in a segment of a vein to resemble that of endothelial cells in arterial tissue. With an arterial identity, the cells and surrounding tissue can undergo endothelial remodeling such that the vein develops the morphology of an artery, which can improve the ability to serve as vessel replacement grafts.

**[0011]** In a preferred embodiment, the method comprises changing the arterial-venous identity of endothelial cells in vascular tissue by transferring an appropriate polynucleotide(s) into the endothelial cells. The polynucleotide(s) encodes a gene or genes capable of inducing endothelial remodeling of the cells such that the cells resemble endothelial cells associated with an artery. Preferred genes for use in this method include those that function to allow arteries and veins to develop distinct identities, such as

endoglin and activin receptor-like kinase 1 (*Alk-1*), and those that are differentially expressed in arteries and veins, such as *ephrin-B2*, *Eph B4*, *elastin* and *CD34*. These genes can be used individually or in any combination. By introducing an appropriate polynucleotide, the endothelial cells of the vascular tissue can remodel and transform their structure to those of an artery.

**[0012]** Furthermore, the present invention also provides methods of treating a patient having an obstructed blood vessel, such as a patient presenting atherosclerosis. In a preferred embodiment, the method comprises harvesting a section of a vein, such as a section of an autologous saphenous vein, changing the arterial-vascular identity of the section by transferring an appropriate polynucleotide into the endothelial cells of the section, removing the obstructed section of a vessel, such as a coronary artery, and grafting the section having the changed arterial-vascular identity for the obstructed section.

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS OF THE INVENTION

**[0013]** The following description of various preferred embodiments of the invention provides examples of the present invention. The embodiments discussed herein are merely exemplary in nature, and are not intended to limit the scope of the invention in any manner. Rather, the description of these preferred embodiments serves to enable a person or ordinary skill in the relevant art to practice the present invention.

**[0014]** In one embodiment, the present invention provides methods and compositions for manipulating the arterial-venous identity of endothelial cells. Manipulation of the arterial-venous identity is accomplished by transferring one or more polynucleotides, or products thereof, that encode one or more genes capable of inducing remodeling of the cells such that the cells resemble endothelial cells associated with an artery. The polynucleotide encodes genes that belong to one or both of the following classes:

**[0015]** 1) genes that have a function of allowing endothelial cells to develop distinct artery or vein identities; and

**[0016]** 2) genes that are differentially expressed in endothelial cells of arteries and veins.

**[0017]** The development of arterial-venous identity is one step in the pathway that allows embryonic endothelial tubes to develop into either of these types of vessels. Furthermore, the inventor has discovered that insertion of the polynucleotide described above into venous endothelial cells allows the cells to remodel into arterial endothelial cells. The development of an arterial identity is measured by the appearance of arterial structural features.

**[0018]** The first class of genes that can be used comprises those genes that have a function of allowing endothelial cells, during embryonic development, to develop distinct identities as being either arterial or venous. During development, vascular remodeling and endothelial maturation produce the final vasculature system. To form an organized vascular network, a hierarchy of major and minor vessels that efficiently transport blood to and from tissues must be established. The formation of a mature hierarchical vascular system forms in two steps. The first step involves the differentiation, rapid proliferation and tube formation of endothelial cells. This process results in the formation of a meshwork of interconnected and homogeneously sized endothelial tubes. In the second stage, vascular remodeling and endothelial maturation occurs. Endothelial tubes must be distinguished as arterial or venous, and an organized network is formed through differential growth, apoptosis, and sprouting of endothelial tubes. This process of remodeling leads to a well-defined vascular network that efficiently supplies blood to and removes waste from the target tissue or tumor. Endoglin and activin receptor-like kinase 1 (Alk1) function to initiate the switch from stage 1-endothelial differentiation and rapid proliferation and stage 2-endothelial maturation and vascular remodeling. (See generally, Ferrara N, and Alitalo, K. *Nat. Med.* 5:1359-64 (1999), Folkman J., and D'Amore P.A., *Cell* 87:1153-1155 (1996), Gale N.W., and Yancopoulos G.D., *Genes Dev* 13(9):1055-66 (1999), Inducing Alk-1 and

endoglin function will promote maturation and the molecular program needed to distinguish arteries from veins. Disrupting the function of these genes will prevent a nascent endothelial network from forming a highly organized network. Thus, blocking the function of these genes may prevent pathologic neovascularization, processes that are critical for cancer growth and diabetic retinopathy. See, for examples, Li, D.Y., et al., *Science* 284:1534-1537 (1999) and Urness, L.D., et al., *Nature Genetics* 26:328-331 (2000). Examples of genes belonging to this first class include *endoglin* and activin receptor-like kinase 1 (*Alk-1*).

**[0019]** Endoglin is a transforming growth factor- $\beta$  (TGF- $\beta$ ) binding protein expressed on the surface of endothelial cells. TGF- $\beta$  signaling is required for vasculogenesis, the first stage of vascular development. During vasculogenesis, the primary capillary network, composed of interconnected and homogenously sized endothelial tubes, is formed. Indeed, mice lacking *endoglin* die at an early age due to defective vascular development characterized by poor smooth muscle development and arrested endothelial remodeling. Consequently, *endoglin* is essential for the second stage of vascular development, angiogenesis, in which the primary endothelial network is remodeled into a mature circulatory system. See generally Li, D.Y., et al., *Science* 284:1534-1537 (1999).

**[0020]** The cDNA encoding *endoglin* has been described. (Gougos, A. and Letarte, M., *J. Biol. Chem.* 265(15): 8361-8364 (1990)). The sequence is appended hereto as SEQ ID NO. 1.

**[0021]** The *Alk-1* gene encodes a serine/threonine kinase receptor for the TGF- $\beta$  superfamily of growth factors (ten, Dijke, P., et al, *Science* 264 (5155): 101-4 (1994); ten, Dijke, P., et al., *Oncogene* 10: 2879-87 (1993); Attisano, L. & Wrana, J.L., *Cytokines and Growth Factor Reviews* 7(4): 327-339 (1996)). The receptor encoded by *Alk-1* is highly expressed in the endothelium (Roelen, B.A., et al, *Dev. Dyn.* 209(4): 418-30 (1997)). Also,

loss-of-function mutations of *Alk-1* are responsible for a human vascular dysplasia characterized by arteriovenous malformations (Guttmacher, A.E., et al., *N. Engl. J. Med.* 333(14): 918-924 (1995); Johnson, D.W., et al., *Nat. Genet.* 13(2): 189-95 (1996)). Furthermore, anatomical, molecular, and functional distinctions between arteries and veins are lost in mice lacking *Alk-1*. Lastly, *Alk-1* is required for successful embryonic development of distinct arterial and venous vascular beds (Id.).

**[0022]** The cDNA encoding *Alk-1* has been described (ten Dijke, P.P., et al., *Oncogene* 8(10): 2879-2887 (1993)). The sequence appended hereto as SEQ ID NO. 2

**[0023]** The second class of genes that can be used in the arterial molecular program comprises those genes that are differentially expressed in the endothelial cells of arteries and veins. As used herein, the term "differentially expressed" refers to the relative extent of expression of a gene in an endothelial cell in an artery as compared to an endothelial cell in a vein. Examples of genes belonging to this second class include *ephrin-B2*, *EphB4*, *elastin*, and *CD34*. See, for example, Urness, L.D., et al., *Nature Genetics* 26:328-331 (2000).

**[0024]** The *ephrin-B2* gene encodes an arterial specific molecular marker that is expressed prior to the appearance of any structural or functional differences between arteries and veins (Adams, R.H., et al. *Genes Dev.* 13:3 295-306 (1999), Wang, H.U., et al., *Cell* 93(5): 741-53 (1998)). Also, while mice lacking the *ephrin-B2* gene or the gene for the ephrin-B2 receptor, *EphB4*, develop distinct arterial and venous domains, these mice experience defective endothelial remodeling (Id.; Gerety, S.S., et al., *Mol Cell* 4:403-14 (1999)). Thus, while *ephrin-B2* and *EphB4* are important arterial markers, they do not regulate the specification of endothelial tubes to become arteries and veins. Indeed, mice lacking the *Alk-1* gene fail to express normal levels of these markers despite the presence of an extensive endothelial network. (Urness, L.D., et al., *Nature Genetics* 26: 328-331 (2000)).



**[0025]** The cDNA encoding *ephrin-B2* has been described. (Bennett, B.D., et al., *Proc. Natl. Acad. Sci. U.S.A.* 92(6): 1866-1870 (1995)). The sequence is appended hereto as SEQ ID NO. 3

**[0026]** The cDNA encoding EphB4 appended hereto as SEQ ID NO. 4

**[0027]** Elastin is the main component of the extracellular matrix of arteries. Elastin has both structural and developmental roles. During arterial development, elastin controls proliferation of smooth muscle and stabilizes arterial structure. Indeed, mice lacking *elastin* die of an obstructive arterial disease resulting from subendothelial cell proliferation and reorganization of smooth muscle. (See Li, D.Y., et al., *Nature* 393:276-280 (1998)).

**[0028]** The cDNA for *elastin* has been described (Faszio, M.J., et al., *J. Invest. Dermatol.* 91(5) 458-464 (1998)). The sequence is appended hereto as SEQ ID NO. 5.

**[0029]** The *CD34* gene encodes a cell surface glycoprotein that is expressed in early blood vessels, as well as on various hematopoietic cells (See, Wood, H.B., et al., *Blood* 90(6): 2300-2311 (1977)).

**[0030]** The cDNA encoding *CD34* has been described (NCBI Annotation Project, Direct Submission, 7-16-2001). The sequence is appended hereto as SEQ ID NO. 6

**[0031]** Preferably, transferring the polynucleotide(s) into an endothelial cell having a venous identity is accomplished by transferring an expression vector comprising one or more of the genes described above. Suitable expression vectors useful in accordance with the present invention include eukaryotic, plasmid and viral vectors, and combinations thereof. Examples of useful viral vectors include recombinant viral vectors such as adenoviral, retroviral, herpesviral, pox viral, and adeno-associated viral vectors. Preferably, the polynucleotides are contained within the expression vector. Also preferable, the expression vector is adapted to introduce the polynucleotide into the endothelial cells.

**[0032]** The transferring of the polynucleotide into the endothelial cells can occur in vivo or ex vivo. Preferably, the transferring occurs ex vivo on a vessel segment harvested

from a patient. Conventional transduction techniques can be utilized to carry out the ex vivo transferring of the polynucleotide into the endothelial cells when viral vectors are used. Examples of suitable transduction techniques include those described in Kibbe, M.R., et al., *J. Vasc. Surg.* 34(1): 156-65 (2001) and Moawad, J., et al., *Ann. Vasc. Surg.* 15(3):367-73 (2001). The transduction should be carried out using a sufficient number of vector particles to ensure adequate transferring of the polynucleotide. Also, the transduction should be carried out under culturing conditions that are conducive to the viability of the endothelial cells as well as the transduction by the vector. Preferred number of vector particles and length of transduction period for changing the arterial venous identity of a segment of a saphenous vein are between approximately  $1 \times 10^8$  and  $1 \times 10^{12}$  viral particles for 15 to 45 minutes. Particularly preferable, approximately  $1 \times 10^{10}$  to  $1 \times 10^{12}$  viral particles are exposed to the vein segment for approximately 30 minutes. Most preferable, approximately  $1 \times 10^{11}$  viral particles are exposed to the endothelial cells of the vein segment for approximately 30 minutes.

**[0033]** The genes may be encoded on a plasmid or other similar construct and then incorporated into the vector. Conventional molecular biology techniques can be employed to create suitable constructs for use in the present invention.

**[0034]** Preferred viral vectors include recombinant retroviral and adeno-associated viral vectors. Recombinant retroviral vectors are frequently used for gene transfer, and methods for constructing such vectors are known in the art (Hodgson, *Bio/Technology* 13: 222-225 (1995); Miyano-hara, et al., *Proc. Natl. Acad. Sci. USA* 85: 6538-6542 (1988); Rosenberg, et al., *New Engl. J. Med.* 323: 570-578 (1990)). Preferably, retroviral vectors with impaired ability to replicate and transform are used.

**[0035]** Methods for producing recombinant adeno-associated viral (AAV) vectors are also known in the art. Briefly, a suitable producer cell line is transfected with an AAV vector containing the gene of interest, which can be encoded on a plasmid. AAV helper

functions (i.e., the products of the AAV rep and cap genes) and accessory functions, which are typically derived from a helper virus, such as adenovirus or herpesvirus, are then expressed in the producer cell. Once these factors come together, the gene(s) of interest is (are) replicated and packaged as though it were a wild-type AAV genome, forming a recombinant virion. When cells, such as endothelial cells, are infected with the resulting AAV virions, the gene(s) of interest enter the cell and is (are) expressed. Because the cells lack the rep and cap genes and the helper virus accessory function genes, the rAAV are replication defective; that is, they cannot further replicate and package their genomes. Similarly, without a source of rep and cap genes, wild-type AAV cannot be formed in the infected cell. For a detailed discussion on the production of rAAV virions, see United States Patent No. 6,001,650 to Colosi for HIGH-EFFICIENCY WILD-TYPE -FREE AAV HELPER FUNCTIONS.

**[0036]** The polynucleotides encoding the gene(s) of interest can be inserted into the expression vectors and used for cell transfection using conventional recombinant techniques, such as those described by Sambrook, Fritsch & Maniatis, in "Molecular Cloning, A Laboratory Manual" (2d ed): pp. E.5 (*Cold Spring Harbor Press*, Cold Spring Harbor, N.Y. 1989). Alternatively, the expression vectors can be prepared using homologous recombination techniques, such as those described by Davidson, et al., *Nature Gen.* 3: 219-223. (1993) and Lemarchand, *Proc. Natl. Acad. Sci. USA* 89(14): 6482-6486 (1992).

**[0037]** The expression vectors of the present invention can additionally contain regulatory elements such as promoters, as well as selection markers, such as antibiotic resistance genes. Furthermore, the expression vectors can include tags that allow for binding of the protein of interest to a binding agent of some sort, which can be used to facilitate purification and/or localization and targeting efforts. Various such tags are known to those skilled in the art. Examples include F<sub>c</sub> receptors and Hexo-histidine tags.

**[0038]** It is well established that viral vectors will be taken up into and integrated into cells *in vivo*, to eventually express the viral DNA, including any inserted constructs (Nabel, United States Patent No. 5,328,470; Yoshimura, et al., *J. Biol. Chem.* 268(4): 2300-2303 (1993); Crystal, *AM. J. Med.* 92(6A): 445-525 (1992); Lemarchand, et al., *Proc. Natl. Acad. Sci. USA* 89(14): 6482-6486 (1992)).

**[0039]** Alternatively, non-viral methods can be used to introduce the polynucleotides into the endothelial cells. Essentially, any suitable method for introducing DNA into cells for later expression can be utilized. For example, techniques such as calcium phosphate co-precipitation (Graham, et al., *Viol.* 52: 456-467 (1973)), direct micro-injection of DNA into cells (Capecchi, *Cell* 22: 479-488 (1980)), liposome-mediated gene transfer (Mannino, et al., *BioTechniques* 6: 682-690 (1988), lipid-mediated transfection (Felgner, et al., *Proc. Natl. Acad. Sci. USA* 84: 7413-7417 (1987)), delivery using DNA-coated stents placed at a target site by a catheter, and nucleic acid delivery using high-velocity microprojectiles (Klein, et al., *Nature* 327: 70-73 (1987)) can be used. Furthermore, electroporation methods for introducing DNA into cells and tissues can be used (Shigekawa, et al., *BioTechniques* 6: 742-751 (1988)).

**[0040]** Those skilled in the art will readily recognize that the various genes introduced into endothelial cells, using either viral or non-viral methods, may be operably linked to control elements such as promoters and enhancers, that are capable of driving or repressing gene expression under appropriate conditions. Termination signals, such as polyadenylation sites, can also be included. Control elements, such as inducible promoters, that allow controlled expression of the gene of interest are available. For example, an ecdysone-inducible promoter can be utilized to regulate gene expression. (See, e.g., Stratagenes; Complete Control™ Inducible Mammalian Expression System Instruction Manual - available online at <http://www.stratagene.com/manuals/index.shtml>). Other examples of suitable inducible promoters that are functional in mammalian cells

include those that are induced (or repressed) by tetracycline and its derivatives, RU486, and rapamycin and its derivatives (See, e.g. Grossen & Brujard, *Proc. Natl. Acad. Sci. USA* 89: 5547-5551 (1992); Wang, et al., *Gene Therapy*, 4: 432-441 (1997); and Riviera, et al., *Nature Medicine* 2: 1028-1032 (1996).

**[0041]** The manipulation of the arterial-vascular identity of endothelial cells may also be accomplished by introducing the products of one or more of the above-mentioned genes into the endothelial cells. The gene products may be produced using standard recombinant techniques known to those skilled in the art (See, generally, Sambrook, et al., (*supra.*)). Recombinantly produced gene products may be purified using conventional purification schemes, such as affinity chromatography, size-exclusion, filtration, precipitation, and other suitable techniques. The gene products can be introduced into the endothelial cells using techniques such as microinjection and protein transduction (see, e.g., Schwarze, et al, *Science* 285: 1569-1572 (1999)).

**[0042]** The present invention also provides a composition comprising a blood vessel, such as a section of a vein or a vascular graft, having endothelial cells comprising an exogenously supplied polynucleotide encoding a gene that is capable of inducing endothelial remodeling. The gene can be any of the genes described above in the description of the methods of the present invention. Thus, the gene can comprise *endoglin*, *Alk-1*, *ephrin-B2*, *EphB4*, *elastin*, and/or *CD34*. The compositions of the present invention are useful as grafts to replace sections of arteries containing obstructions, such as coronary arteries affected by atherosclerosis.

**[0043]** In one embodiment, the composition of the present invention comprises a section of an autologous vein, i.e., a section of a vein of the patient ultimately receiving the graft. The use of autologous tissue eliminates any tissue rejection concerns.

**[0044]** Any suitable vein can be utilized for the vein section. The choice of vein will depend on various factors, such as ease of harvesting, ability of the vein to tolerate

removal of a section, and the relative capacity of the vessel as compared to that of the obstructed vessel. Preferred veins include the saphenous vein of the leg. Particularly preferable, the vein section comprises a section of the internal or long saphenous vein. Sections of these preferred veins can be readily harvested by surgical techniques known to those skilled in the art.

**[0045]** Importantly, the vein section must include the endothelial cell layer (endothelium) such that the polynucleotide and gene can be introduced into the endothelial cells. The polynucleotide can encode any combination of the genes discussed above. Also, the polynucleotide can be introduced into the endothelial cells of the vein section according to any suitable technique, such as those described above.

**[0046]** Alternatively, the composition can comprise an engineered blood vessel comprising endothelial cells.

**[0047]** Engineered blood vessels are vessels fabricated from tissue engineering procedures. This class of vessel includes synthetic material in combination with natural cells, such as endothelial cells, as well as cultured vessels produced from natural materials, such as smooth muscle and endothelial cells. Examples of such vessels, as well as techniques for their production, can be found in Huynh, T., et al., *Nature Biotechnology*, 17: 1083-1086 (1999); Niklason, L.E., et al., *Science* 284: 489-493 (1999); L'Heureux, et al, *FASEB J.* 12: 47-56 (1998); and Campbell, J.H., et al., *Cir. Res.* 85: 1173-1178 (1999).

**[0048]** The expression vectors of the present invention can be introduced into endothelial cells of an engineered blood vessel in the same manner as that described above for segments of natural veins.

**[0049]** The present invention also provides a method of treating a patient having an obstructed blood vessel. The method of treatment can be practiced on any mammal, but is particularly well-suited for treating humans. The method is particularly well-suited for

treating patients having obstructed arteries, such as coronary arteries affected by atherosclerosis.

**[0050]** As detailed above, surgical grafting of a vascular graft in place of the obstructed artery is a common surgical technique for treating patients with obstructed vessels. The method of the present invention can be practiced in accordance with guidelines known in the art, such as those relating to the need for bypass grafting as a function of the fraction of the vessel blocked.

**[0051]** In a preferred embodiment, the method of treatment comprises providing a graft comprising endothelial cells, changing the arterial-vascular identity of the endothelial cells by transferring a polynucleotide encoding a gene capable of inducing endothelial remodeling into the endothelial cells, removing an obstructed section of a vessel of the patient, and grafting the graft having the endothelial cells with changed arterial-vascular identity in place of the removed obstructed section. The arterial-vascular identity of the endothelial cells can be changed ex vivo prior to grafting, or in vivo after grafting.

**[0052]** The graft can comprise a vein section or an engineered blood vessel, as described above. If the graft comprises a vein section, the section preferably comprises a section of an autologous vein, and particularly preferably comprises a section of a saphenous vein of the patient. Also, if the graft comprises a vein section, the method may further comprise harvesting the vein section from a vein of the patient. The harvesting can be accomplished according to conventional techniques known in the art.

**[0053]** The changing the arterial-vascular identity of the endothelial cells by transferring an appropriate polynucleotide into the endothelial cells can be accomplished according to the methods of the present invention, detailed above.

**[0054]** The removing an obstructed section of a vessel of a patient and the grafting of the graft in place of the removed obstructed section can both be accomplished according to conventional techniques known in the art.

Blank Upon Filing



**Example**

**[0055]** The present invention can be carried out to alter the arterial-venous identity of endothelial cells in a vein segment in an ex vivo environment. This preferred method is particularly well-suited for treating a segment of a vein that has been harvested from a patient suffering from an obstructed blood vessel. The treated vein segment can be used as a graft to replace an obstructed section of the obstructed vessel.

**[0056]** When practicing this method, a segment of a saphenous vein of the patient will be harvested according to conventional surgical procedures. The section will be dissected to provide a segment that is of a suitable length, i.e. a length sufficient to allow the segment to serve as a replacement for the obstructed section of the obstructed vessel.

**[0057]** The vein segment will be passively transduced with an adenoviral vector carrying one or more genes encoding *Alk-1*, *endoglin*, *ephrin-B2*, *Eph-B4*, *elastin*, and *CD34*. The transduction will be carried out using approximately  $1 \times 10^{11}$  adenoviral vector particles for 30 minutes using standard techniques. Examples of suitable transduction techniques are described in Kibbe, M.R., et al., *J. Vasc. Surg.* 34(1): 156-65 (2001) and Moawad, J., et al., *Ann. Vasc. Surg.* 15(3):367-73 (2001).

**[0058]** The obstructed section of the obstructed vessel will be removed using conventional surgical techniques. Lastly, the transduced vein segment will be interposed as a graft in place of the obstructed section. Thus, if a coronary artery was the obstructed vessel, the transduced vein segment will be grafted into the coronary circulation in place of the obstructed section. The grafting can occur in the peripheral circulation, if needed, based on the location of the obstructed section of the obstructed vessel.

**[0059]** All references cited and otherwise referred to herein are hereby incorporated in their entirety, except to the extent to which they may contradict any definition or statement herein.

**[0060]** The foregoing disclosure is the best mode devised by the inventor for practicing the invention. It is apparent, however, that several variations in accordance with the present invention may be conceivable to one of ordinary skill in the relevant art. Inasmuch as the foregoing disclosure is intended to enable such person to practice the instant invention, it should not be construed to be limited thereby, but should be construed to include such aforementioned variations. As such, the present invention should be limited only by the spirit and scope of the following claims.

## CLAIMS

1. A method for inducing arterial morphology in a vein, comprising:  
contacting endothelial cells in said vein to at least one polynucleotide encoding a gene that is capable of inducing endothelial remodeling for a time sufficient to transfer the polynucleotide into the endothelial cells.
2. The method of claim 1, wherein said vein is a mammalian vein.
3. The method of claim 1, wherein the vein is a human vein.
4. The method of claim 3, wherein the vein is a saphenous vein.
5. The method of claim 1, wherein the gene encodes *endoglin*, *Alk-1* or both.
6. The method of claim 1, wherein the gene encodes one or more of *ephrin-B2*, *EphB4*, *elastin* and *CD34*.
7. The method of claim 1, wherein the polynucleotide is contained within an expression vector adapted to introduce the polynucleotide into the cells.
8. The method of claim 7, wherein the expression vector is a viral vector.
9. The method of claim 8, wherein the viral vector is an adenoviral vector, a herpesviral vector, a pox viral vector, or an adeno-associated viral vector.
10. A method of treating a patient having an obstructed blood vessel, comprising:

providing a graft comprising endothelial cells;  
contacting the endothelial cells of the graft to at least one polynucleotide encoding a gene that is capable of inducing endothelial remodeling for a time sufficient to transfer the polynucleotide into the endothelial cells;  
removing a section of said obstructed blood vessel; and  
grafting the graft in place of the removed section of said obstructed blood vessel.

11. The method of claim 10, wherein providing a graft comprises harvesting a section of a vein from said patient.

12. The method of claim 11, wherein the vein is a saphenous vein of said patient.

13. The method of claim 10, wherein the gene encodes *endoglin*, *Alk-1*, or both.

14. The method of claim 10, wherein the gene encodes one or more of *ephrin-B2*, *EphB4*, *elastin* and *CD34*.

15. The method of claim 10, wherein the polynucleotide is contained within an expression vector adapted to introduce the polynucleotide into the cells.

16. The method of claim 15, wherein the expression vector is a viral vector.

17. The method of claim 16, wherein the viral vector is an adenoviral vector, a retroviral vector, a herpesviral vector, a pox viral vector, or an adeno-associated viral vector.

18. A blood vessel, comprising endothelial cells comprising an exogenously supplied polynucleotide encoding a gene that is capable of inducing endothelial remodeling in the endothelial cells.

19. A blood vessel in accordance with claim 18, wherein the vessel is a section of a mammalian vein.

20. A blood vessel in accordance with claim 19, wherein the vessel is a section of a human vein.

21. A blood vessel in accordance with claim 20, wherein the vessel is a section of a saphenous vein.

22. A blood vessel in accordance with claim 18, wherein the gene encodes *endoglin*, *Alk-1* or both.

23. A blood vessel in accordance with claim 18, wherein the gene encodes one or more of *ephrin-B2*, *EphB4*, *elastin*, and *CD34*.

## SEQUENCE LISTING

<110> The University of Utah

<120> Manipulation of Arterial-Venous Identity

<130> 10402-011

<160> 6

<170> PatentIn version 3.1

<210> 1

<211> 3142

<212> DNA

<213> Homo sapiens

<400> 1

cctgggccgg ccgggctgga tgagccggga gtcacctgct gccggtcata ccacagcc  
tt 60

catctgcgcc ctggggccag gactgctgct gtcactgcca tccattggag ccagcac  
cc 120

cctccccgcc catccttcgg acagcaactc cagcccagcc ccgcgtccct gtgtccac  
tt 180

ctcctgaccc ctcgggccgcc accccagaag gctggagcag ggacgccgtc gtcccggc  
cg 240

cctgtccccc tcgggtcccc gtgcgagccc acgccggccc cggtgcccgc ccgcagcc  
ct 300

gccactggac acaggataag gccacgcga caggccccca cgtggacagc atggaccg  
cg 360

gcacgtccc tctggctgtt gccctgctgc tggccagctg cagcctcagc ccacaag  
tc 420

ttgcagaaac agtccattgt gaccttcagc ctgtgggccc cgagaggggc gaggtgac  
at 480

ataccactag ccaggctctg aagggtgctg tggctcaggc cccaatgcc atccttga  
ag 540

tccatgtcct cttcctggag ttcccaacgg gccpgtcaca gctggagctg actctcca  
gg 600

catccaagca aaatggcacc tggccccgag aggtgcttct ggtcctcagt gtaaacag  
ca 660

gtgtcttccct gcactctccag gccctgggaa tccactgca cttggcctac aattccag

cc 720

tggtcacctt ccaagagccc ccgggggtca acaccacaga gctgccatcc ttcccca  
ga 780

cccagatcct tgagtgggca gctgagaggg gcccacacac ctctgctgct gagctgaa  
tg 840

acccccagag catcctcctc cgactgggccc aagcccaggg gtcactgtcc ttctgcat  
gc 900

tggaagccag ccaggacatg ggccgcacgc tcgagtggcg gccgcgtact ccagcctt  
gg 960

tccggggctg ccacttggaa ggcgtggccc gccacaagga ggcgcacatc ctgagggt  
cc 1020

tgccgggcca ctcgcccggg ccccggaagg tgacgggtgaa ggtggaactg agctgcgc  
ac 1080

ccggggatct cgatgccgtc ctcatcctgc aggggtcccc ctacgtgtcc tggctcat  
cg 1140

acgccaacca caacatgcag atctggacca ctggagaata ctcttcaag atctttcc  
ag 1200

agaaaaacat tcgtggcttc aagctcccag acacacctca aggcctcctg ggggaggg  
cc 1260

ggatgctcaa tgccagcatt gtggcatcct tcgtggagct accgctggcc agcattgt  
ct 1320

cacttcatgc ctccagctgc ggtggtaggc tgcagacctc accgcaccg atccagac  
ca 1380

ctctcccaa ggacacttgt agcccggagc tgctcatgtc cttgatccag acaaagt  
tg 1440

ccgacgagc catgaccctg gtactaaaga aagagcttgt tgcgcatttg aagtgcac  
ca 1500

tcacgggcct gaccttctgg gaccccagct gtgaggcaga ggacaggggt gacaagtt  
tg 1560

tcttgccag tgcttactcc agctgtggca tgcaggtgtc agcaagtatg atcagcaa  
tg 1620

aggcgggtgt caatatcctg tcgagctcat caccacagcg gaaaaaggtg cactgcct  
ca 1680

acatggacag cctctctttc cagctgggccc tctacctcag cccacacttc ctccaggg  
ct 1740

ccaacacccat cgagccgggg cagcagagct ttgtgcaggt cagagtgtcc ccatccgt  
ct 1800

ccgagttcct gctccagtta gacagctgcc acctggactt ggggcctgag ggaggcac  
cg 1860

tggaactcat ccagggccgg gcggccaagg gcaactgtgt gagcctgctg tccccaag  
cc 1920

ccgaggggtga cccgcgcttc agcttctctc tccacttcta cacagtaccc atacccaa  
aa 1980

ccggcaccct cagctgcacg gtagccctgc gtcccaagac cgggtctcaa gaccagga  
ag 2040

tccataggac tgtcttcatg cgcttgaaca tcatcagccc tgacctgtct ggttgcac  
aa 2100

gcaaaggcct cgtcctgccc gccgtgctgg gcatcacctt tgggtgccttc ctcatcgg  
gg 2160

ccctgctcac tgctgcactc tggtagatct actcgcacac gcgtgagtag cccaggcc  
cc 2220

cacagtgagc atgccggggc cctccatcca cccggggggag cccagtgaag cctctgag  
gg 2280

attgaggggc cctggcagga cctgacctc cgcccctgcc cccgctcccg ctcccagg  
tt 2340

ccccagcaa gcgggagccc gtggtggcgg tggctgcccc ggcctcctcg gagagcag  
ca 2400

gcaccaacca cagcatcggg agcaccacaga gcacccctg ctccaccagc agcatggc  
at 2460

agccccggcc ccccgcgctc gccagcagg agagactgag cagccgccag ctgggagc  
ac 2520

tgggtgtgaac tcaccctggg agccagtcct ccactcgacc cagaatggag cctgctct  
cc 2580

gcgcctaccc ttcccgctc cctctcagag gcctgctgcc agtgcagcca ctggcttg  
ga 2640

acaccttggg gtccctccac cccacagaac cttcaaccca gtgggtctgg gatattgg  
tg 2700

cccaggagac agaccattg ccacgtgtt gtaaaaaccc aagtcctgt catttgaa  
cc 2760



tggatccagc actggtgaac tgagctgggc aggaaggag aacttgaaac agattcag  
gc 2820

cagcccagcc aggccaacag cacctccccg ctgggaagag aagagggccc agcccaga  
gc 2880

cacctggatc tatccctgcg gcctccacac ctgaacttgc ctaactaact ggcagggg  
ag 2940

acaggagcct agcggagccc agcctgggag cccagagggg ggcaagaaca gtgggcgt  
tg 3000

ggagcctagc tcctgccaca tggagcccc tctgccggtc ggcagccag cagagggg  
ga 3060

gtagccaagc tgcttgtcct gggcctgccc ctgtgtattc accaccaata aatcagac  
ca 3120

tgaaacctga aaaaaaaaaa aa  
3142

<210> 2

<211> 1970

<212> DNA

<213> Homo sapiens

<400> 2

aggaaacggt ttattaggag ggagtgggtg agctgggcca ggcaggaaga cgctggaa  
ta 60

agaaacattt ttgctccagc cccatccca gtcccgggag gctgcgcgc cagctgcg  
cc 120

gagcgagccc ctcccgggt ccagcccggg cgggggcgc gccggacccc agcccgc  
gt 180

ccagcgctgg cggtgcaact gcggccgcg ggtggagggg aggtggcccc ggtccgc  
ga 240

aggctagcgc cccgccaccc gcagagcggg cccagagggg ccatgacctt gggctccc  
cc 300

aggaaaggcc ttctgatgct gctgatggcc ttggtgacct agggagacct tgtgaagc  
cg 360

tctcggggcc cgctggtgac ctgcacgtgt gagagcccac attgcaaggg gcctacct  
gc 420

cggggggcct ggtgcacagt agtgctggtg cgggaggagg ggaggcacc ccaggaac  
at 480

cggggctgcg ggaacttgca cagggagctc tgcagggggc gccccaccga gttcgtca  
ac 540

cactactgct gcgacagcca cctctgcaac cacaacgtgt ccctgggtgct ggaggcca  
cc 600

caacctcctt cggagcagcc gggaacagat ggccagctgg ccctgatcct gggccccg  
tg 660

ctggccttgc tggccctggg gccctgggt gtcctgggccc tgtggcatgt ccgacgga  
gg 720

caggagaagc agcgtggcct gcacagcgag ctgggagagt ccagtctcat cctgaaag  
ca 780

tctgagcagg gcgacacgat gttggggggac ctcctggaca gtgactgcac cacaggga  
gt 840

ggctcagggc tccccttcct ggtgcagagg acagtggcac ggcaggttgc cttgggtgg  
ag 900

tgtgtgggaa aaggccgcta tggcgaagtg tggcggggct tgtggcacgg tgagagtg  
tg 960

gccgtcaaga tcttctctc gagggatgaa cagtccctggg tccgggagac tgagatct  
at 1020

aacacagtat tgctcagaca cgacaacatc ctaggcttca tcgcctcaga catgacct  
cc 1080

cgcaactcga gcaagcagct gtggctcacc acgcactacc acgagcacgg ctccctct  
ac 1140

gactttctgc agagacagac gctggagccc catctggctc tgaggctagc tgtgtccg  
cg 1200

gcatgcggcc tggcgcacct gcacgtggag atcttcggta cacagggcaa accagcca  
tt 1260

gcccaccgcg acttcaagag ccgcaatgtg ctggtcaaga gcaacctgca gtgttgca  
tc 1320

gccgacctgg gcctggctgt gatgcactca cagggcagcg attacctgga catcggca  
ac 1380

aacccgagag tgggcaccaa gcggtacatg gcacccgagg tgctggacga gcagatcc  
gc 1440

acggactgct ttgagtccta caagtggact gacatctggg cctttggcct ggtgctgt  
gg 1500

gagattgccc gccggaccat cgtgaatggc atcgtggagg actatagacc acccttct

at 1560

gatgtggtgc ccaatgaccc cagctttgag gacatgaaga aggtggtgtg tgtggatc  
ag 1620

cagaccccca ccacccctaa ccggctggct gcagaccogg tcctctcagg cctagctc  
ag 1680

atgatgcggg agtgctggta cccaaacccc tctgcccgac tcaccggcgt gcggatca  
ag 1740

aagacactac aaaaaattag caacagtcca gagaagccta aagtgattca atagccca  
gg 1800

agcacctgat tcctttctgc ctgcaggggg ctgggggggt ggggggcagt ggatggtg  
cc 1860

ctatctgggt agaggtagtg tgagtgtggt gtgtgctggg gatgggcagc tgcgcctg  
cc 1920

tgctcgcccc ccagcccacc cagccaaaaa tacagctggg ctgaaacctg  
1970

<210> 3

<211> 2902

<212> DNA

<213> Homo sapiens

<400> 3

cacagccatg gctgtgagaa gggactccgt gtggaagtac tgctgggggtg ttttgatg  
gt 60

tttatgcaga actgcgattt ccaaatcgat agtttttagag cctatctatt ggaattcc  
tc 120

gaactccaaa tttctacctg gacaaggact ggtactatac ccacagatag gagacaaa  
tt 180

ggatattatt tgccccaaag tggactctaa aactgttggc cagtatgaat attataaa  
gt 240

ttatatgggt gataaagacc aagcagacag atgcactatt aagaaggaaa ataccctt  
ct 300

cctcaactgt gccaaaccag accaagatat caaatccacc atcaagtttc aagaattc  
ag 360

ccctaacctc tgggggtctag aatttcagaa gaacaaagat tattacatta tatctaca  
tc 420

aatgggtct ttggagggcc tggataacca ggagggaggg gtgtgccaga caagagcc

at 480

gaagatcctc atgaaagttg gacaagatgc aagttctgct ggatcaacca ggaataaa  
ga 540

tccaacaaga cgtccagaac tagaagctgg tacaaatgga agaagttcga caacaagt  
cc 600

ctttgtaaaa ccaaattccag gttctagcac agacggcaac agcgccggac attcgggg  
aa 660

caacatcctc ggttccgaag tggccttatt tgcagggatt gcttcaggat gcatcatc  
tt 720

catcgtcctc atcatcacgc tgggtggctct cttgctgaag taccggagga gacacagg  
aa 780

gcactcgccg cagcacacga ccacgctgtc gctcagcaca ctggccacac ccaagcgc  
ag 840

cggcaacaac aacggctcag agcccagtga cattatcatc ccgctaagga ctgcggac  
ag 900

cgtcttctgc cctcactacg agaaggtcag cggggactac gggcaccggt tgtacatc  
gt 960

ccaggagatg cccccgcaga gcccggcgaa catttactac aaggtctgag agggaccc  
tg 1020

gtggtacctg tgctttccca gaggacacct aatgtcccga tgcctccctt gagggttt  
ga 1080

gagcccgctg gctggagaat tgactgaagc acagcaccgg gggagagggg cactcctc  
ct 1140

cggaagagcc cgtcgcgctg gacagcttac ctagtcttgt agcattcggc cttggtga  
ac 1200

acacacgctc cctggaagct ggaagactgt gcagaagacg cccattcggg ctgctgtg  
cc 1260

gcgtcccacg tctcctcctc gaagccatgt gctgcgggtca ctcaggcctc tgcagaag  
cc 1320

aaggggaagac agtggtttgt ggacgagagg gctgtgagca tcctggcagg tgccccag  
ga 1380

tgccacgcct ggaagggccg gcttctgcct ggggtgcatt tccccgcag tgcatacc  
gg 1440

acttgtcaca cggacctcgg gctagttaag gtgtgcaaag atctctagag tttagtcc  
tt 1500

actgtctcac tcgttctggt acccaggggt ctgcagcacc tcacctgaga cctccact  
cc 1560

acatctgcat cactcatgga aactcatgt ctggagtccc ctctccagc cgctggca  
ac 1620

aacagcttca gtccatgggt aatccgttca tagaaattgt gtttgctaac aaggtgcc  
ct 1680

ttagccagat gctaggctgt ctgcaagaa ggctaggagt tcatagaagg gagtgggg  
ct 1740

ggggaaaggg ctggctgcaa ttgcagctca ctgctgctgc ctctgaaaca gaaagttg  
ga 1800

aaggaaaaaa gaaaaaagca attaggtagc acagcacttt ggttttgctg agatcgaa  
ga 1860

ggccagtagg agacacgaca gcacacacag tggattccag tgcattggga ggcactcg  
ct 1920

gttatcaaat agcgatgtgc aggaagaaaa gccctcttc attccgggga acaaagac  
gg 1980

gtattgttgg gaaaggaaca ggcttgagg gaaggagaa agtaggccgc tgatgata  
ta 2040

ttcgggcagg actgttgtgg tactggcaat aagatacaca gctccgagct gtaggaga  
gt 2100

cggtctgctt tggatgattt ttaagcaga ctgagctgct atacttatca cattttat  
ta 2160

aacacagga aagcatttag gagaatagca gagagccaaa tctgacctaa aagttgaa  
aa 2220

gccaaaggtc aaacaggctg taattccatc atcatcggtg ttattaaaga atccttat  
ct 2280

ataaaaggta ggtcagatcc cctcccccc aggttcctcc tccccctccc gattgagc  
ct 2340

tacgacactt tggtttatgc ggtgctgtcc gggtgccagg gctgcagggt cggtactg  
at 2400

ggagcctgca gcgcccgggt ctctgtgtca aggtgaagca catacggcag acctotta  
ga 2460

gtccttaaga cggaagtaaa ttatgatgtc cagggggaga aggaagatag gacgtatt  
ta 2520

taataggtat atagaacaca agggatataa aatgaaagat ttttactaat atatattt  
ta 2580

aggttgacaca cagtacacac cagaagatgt gaaattcatt tgtggcaatt aagtggtc  
cc 2640

aatgctcagc gcttaaaaaa acaaattgga cagctacttc tgggaaaaac aacatcat  
tc 2700

caaaaagaac aataatgaga gcaaattgaa aaataaccaa gtectccgaa ggcatttc  
ac 2760

ggaaccgtag actaggaagt acgagcccca cagagcagga agccgatgtg actgcattc  
at 2820

atatttaaca atgacaagat gttccggcgt ttatttctgc gttgggtttt cccttgcc  
tt 2880

atgggctgaa gtgttctcta ga  
2902

<210> 4

<211> 3945

<212> DNA

<213> Homo sapiens

<400> 4

cgtccacccg cccagggaga gtcagacctg ggggggcgag ggccccccaa actcagtt  
cg 60

gattctaccc gagtgaggcg gcgcatgga gctccgggtg ctgctctgct gggcttcg  
tt 120

ggccgcagct ttggaagaga ccctgctgaa cacaaaattg gaaactgctg atctgaag  
tg 180

ggtgacattc cctcaggtgg acgggcagtg ggaggaactg agcggcctgg atgaggaa  
ca 240

gcacagcgtg cgcacctacg aagtgtgtga cgtgcagcgt gccccgggccc agggccac  
tg 300

gcttcgcaca ggttgggtcc cacggcgggg cgccgtccac gtgtacgcca cgctgcgc  
tt 360

caccatgctc gagtgacctg ccctgcctcg ggctgggcgc tctgcaagg agaccttc  
ac 420

cgtcttctac tatgagagcg atgcggacac ggccacggcc ctcacgccag cctgggatg  
ga 480

gaaccctac atcaaggtgg acacggtggc cgcggagcat ctcacccgga agcgccct  
gg 540

ggccgaggcc accggaagg tgaatgtcaa gacgctgcgt ctgggaccgc tcagcaag  
gc 600

tggcttctac ctggccttcc aggaccaggg tgccctgcatg gccctgctat ccctgcac  
ct 660

cttctacaaa aagtgcgcc agctgactgt gaacctgact cgattcccgg agactgtg  
cc 720

tccggagctg gttgtgccg tggccggtag ctgctgggtg gatgccgtcc ccgcccct  
gg 780

cccagcccc agcctctact gccgtgagga tggccagtgg gccgaacagc cggtcacg  
gg 840

ctgcagctgt gctccgggggt tcgaggcagc tgaggggaac accaagtgcc gagcctgt  
gc 900

ccagggcacc ttcaagcccc tgtcaggaga agggctcctgc cagccatgcc cagccaat  
ag 960

ccactctaac accattggat cagccgtctg ccagtgccgc gtcgggtact tccgggca  
cg 1020

cacagacccc cgggggtgcac cctgcaccac cctccttcg gctccgcgga gcgtgggt  
tc 1080

ccgcctgaac ggctcctccc tgcacctgga atggagtgcc cccctggagt ctgggtggc  
cg 1140

agaggacctc acctacgcc tccgctgccg ggagtgcga cccggaggct cctgtgcg  
cc 1200

ctgcggggga gacctgactt ttgaccccg ccccgggac ctgggtggagc cctgggtg  
gt 1260

ggttcgaggg ctacgtcctg acttcaccta tacctttgag gtcactgcat tgaacggg  
gt 1320

atcctcctta gccacggggc ccgtccatt tgagcctgtc aatgtcacca ctgaccga  
ga 1380

ggtacctcct gcagtgtctg acatccgggt gacgcgggtc tcacccagca gcttgagc  
ct 1440

ggcctgggct gttccccggg caccagtggt ggctgtgctg gactacgagg tcaaatac  
ca 1500

tgagaagggc gccgagggtc ccagcagcgt gcggttcctg aagacgtcag aaaaccgg

gc 1560

agagctgcgg gggctgaagc ggggagccag ctacctggtg caggtagcggg cgcgctct  
ga 1620

ggccggctac gggcccttcg gccaggaaca tcacagccag acccaactgg atgagagc  
ga 1680

gggctggcgg gagcagctgg ccctgattgc gggcacggca gtcgtgggtg tggctctg  
gt 1740

cctggtggtc attgtggctg cagttctctg cctcaggaag cagagcaatg ggagagaa  
gc 1800

agaatattcg gacaaacacg gacagtatct catcggacat ggtactaagg tctacatc  
ga 1860

ccccttcact tatgaagacc ctaatgaggc tgtgagggaa tttgcaaaag agatcgat  
gt 1920

ctcctacgtc aagattgaag aggtgattgg tgcaggtgag tttggcgagg tgtgccgg  
gg 1980

gcggctcaag gccccaggga agaaggagag ctgtgtggca atcaagaccc tgaagggt  
gg 2040

ctacacggag cggcagcggc gtgagtttct gagcgaggcc tccatcatgg gccagttc  
ga 2100

gcaccccaat atcatccgcc tggagggcgt ggtcaccaac agcatgcccg tcatgatt  
ct 2160

cacagagttc atggagaacg gcgccctgga ctccctcctg cggctaaacg acggacag  
tt 2220

cacagtcatc cagctcgtgg gcatgctgcg gggcatcgcc tcgggcatgc ggtacctt  
gc 2280

cgagatgagc tacgtccacc gagacctggc tgctcgcaac atcctagtca acagcaac  
ct 2340

cgtctgcaaa gtgtctgact ttggcctttc ccgattcctg gaggagaact cttccgat  
cc 2400

cacctaacag agctccctgg gaggaagat tcccatccga tggactgccg cggaggcc  
at 2460

tgccttcagg aagttcactt ccgccagtga tgctggagt tacgggattg tgatgtgg  
ga 2520

ggtgatgtca tttggggaga ggccgtactg ggacatgagc aatcaggacg tgatcaat  
gc 2580



cattgaacag gactaccggc tgcccccgcc cccagactgt cccacctccc tccaccag  
ct 2640

catgctggac tgttggcaga aagaccggaa tgcccggccc cgcttcccc aggtggtc  
ag 2700

cgccctggac aagatgatcc ggaaccccg cagcctcaaa atcgtggccc gggagaat  
gg 2760

cggggcctca caccctctcc tggaccagcg gcagcctcac tactcagctt ttggctct  
gt 2820

gggcgagtgg cttcgggcca tcaaaatggg aagatacgaa gaaagtttcg cagccgct  
gg 2880

ctttggctcc ttcgagctgg tcagccagat ctctgctgag gacctgctcc gaatcgga  
gt 2940

cactctggcg ggacaccaga agaaaatctt ggccagtgtc cagcacatga agtcccag  
gc 3000

caagccggga accccgggtg ggacaggagg accggccccg cagtactgac ctgcagga  
ac 3060

tccccacccc agggacaccg cctccccatt ttccggggca gagtggggac tcacagag  
gc 3120

ccccagccct gtgccccgct ggattgcact ttgagcccgt ggggtgagga gttggcaa  
tt 3180

tggagagaca ggatttgggg gttctgccat aataggaggg gaaaatcacc cccagcc  
ac 3240

ctcggggaac tccagaccaa gggtgagggc gcctttccct caggactggg tgtgacca  
ga 3300

ggaaaaggaa gtgcccaaca tctcccagcc tcccagggtg ccccccctac cttgatgg  
gt 3360

gcgttcccgc agaccaaaga gagtgtgact cccttgccag ctccagagtg ggggggct  
gt 3420

cccagggggc aagaaggggt gtcaggggcc agtgacaaaa tcattgggggt ttgtagtc  
cc 3480

aacttgctgc tgtcaccacc aaactcaatc atttttttcc cttgtaaagt cccctccc  
cc 3540

agctgctgcc ttcatattga aggtttttga gttttgtttt tggctttaat tttctccc  
cc 3600

gttccctttt tgtttcttcg ttttgtttt ctaccgtcct tgtcataact ttgtgttg  
ga 3660

gggaacctgt ttcactatgg cctcctttgc ccaagttgaa acaggggccc atcatcat  
gt 3720

ctgtttccag aacagtgcct tgggtcatccc acatccccgg accccgctg ggaccccc  
aa 3780

gctgtgtcct atgaaggggt gtgggggtgag gtagtgaaaa gggcggtagt tgggtggtg  
ga 3840

accagaaaac ggacgccggt gcttggaggg gttcttaaata tatatttaaa aaagtaac  
tt 3900

tttgtataaa taaaagaaaa tgggacgtgt cccagctcca ggggt  
3945

<210> 5  
<211> 2274  
<212> DNA  
<213> Homo sapiens

<400> 5  
atggcggggtc tgacggcggc ggccccgcgg cccggagtcc tctgtcct gctgtcca  
tc 60

ctccaccct ctcggcctgg aggggtccct ggggccattc ctggtggagt tctgggag  
ga 120

gtcttttata caggggctgg tctcgagacc cttggaggag gagcgctggg gcctggag  
gc 180

aaacctctta agccagttcc cggagggcct gcggtgctg gccttggggc agggctcg  
gc 240

gccttccccg cagttacctt tccgggggct ctggtgctg gtggagtggc tgacgctg  
ct 300

gcagcctata aagctgctaa ggctggcgct gggcttggtg gtgtcccagg agttggtg  
gc 360

ttaggagtgt ctgcaggtgc ggtggttcc cagcctggag ccggagtga gcctggga  
aa 420

gtgccgggtg tggggctgcc aggtgtatac ccaggtggcg tgctcccagg agctcgg  
tc 480

cccggtgtgg ggggtgctccc tggagttccc actggagcag gagttaagcc caaggctc  
ca 540

ggtgtaggtg gagcttttgc tggaaatccca ggagttggac cctttggggg accgcaac  
ct 600

ggagtcaccac tggggatatcc catcaaggcc cccaagctgc ctggtggcta tggactgc  
cc 660

tacaccacag ggaaactgcc ctatggctat gggcccggag gagtggctgg tgcagcgg  
gc 720

aaggctggtt acccaacagg gacaggggtt ggccccagg cagcagcagc agcggcag  
ct 780

aaagcagcag caaagttcgg tgctggagca gccggagtcc tccctggtgt tggagggg  
ct 840

ggtgttcctg gcgtgcctgg ggcaattcct ggaattggag gcatcgcagg cgttgga  
ct 900

ccagctgcag ctgcagctgc agcagcagcc gctaaggcag ccaagtatgg agctgctg  
ca 960

ggcttagtgc ctggtgggcc aggctttggc ccgggagtag ttggtgtccc aggagctg  
gc 1020

gttcaggtg ttggtgtccc aggagctggg attccagttg tcccaggtgc tgggatcc  
ca 1080

ggtgctgcgg ttccaggggt tgtgtcacca gaagcagctg ctaaggcagc tgcaaagg  
ca 1140

gccaaatagc gggccaggcc cggagtcgga gttggaggca ttctactta cgggggtg  
ga 1200

gctgggggct ttcccggctt tgggtgtcgga gtcggaggta tccctggagt cgcaggtg  
tc 1260

cctagtgtcg gaggtgttcc cggagtcgga ggtgtcccgg gatttggcat ttccccg  
aa 1320

gctcaggcag cagctgccgc caaggctgcc aagtacggag tggggacccc agcagctg  
ca 1380

gctgctaaag cagccgccaa agccgccag tttgggttag ttctggtgt cggcgtgg  
ct 1440

cctggagttg gcgtggctcc tgggtgtcgt gtggctcctg gatttggctt ggctcctg  
ga 1500

gttggcgtgg ctctggagt tgggtgtggct cctggcgttg gcgtggctcc cggcattg  
gc 1560

cctggtggag ttgcagctgc agcaaaatcc gctgccaagg tggctgccaa agcccagc

tc 1620

cgagctgcag ctgggcttgg tgctggcatc cctggacttg gagttggtgt cggcgctcc  
ct 1680

ggacttggag ttggtgctgg tgttcctgga cttaggagttg gtgctggtgt tcttgggt  
tc 1740

ggggcaggtg cagatgaggg agttaggcgg agcctgtccc ctgagctcag ggaaggag  
at 1800

ccctcctcct ctcagcacct ccccagcacc ccctcatcac ccagggtacc tggagccc  
tg 1860

gctgccgcta aagcagccaa atatggagca gcagtgcctg gggtccttgg agggctcg  
gg 1920

gctctcggtg gagtaggcat ccagggcggg gtggtgggag ccggaccgcg cggcgccg  
ct 1980

gccgcagcca aagctgctgc caaagccgcc cagtttggcc tagtgggagc cgctgggc  
tc 2040

ggaggactcg gagtcggagg gcttggagtt ccaggtgttg ggggccttgg aggtatac  
ct 2100

ccagctgcag ccgctaaagc agctaaatac ggtgctgctg gccttggagg tgccttag  
gg 2160

ggtgccgggc agttcccact tggaggagtg gcagcaagac ctggcttcgg attgtctc  
cc 2220

attttcccag gtggggcctg cctggggaaa gcttgtggcc ggaagagaaa atga  
2274

<210> 6

<211> 2615

<212> DNA

<213> Homo sapiens

<400> 6

ccttttttgg cctcgacggc ggcaaccag cctccctcct aacgccctcc gcctttgg  
ga 60

ccaaccaggg gagctcaagt tagtagcagc caaggagagg cgctgccttg ccaagact  
aa 120

aaaggaggagg gagaagagag gaaaaaagca agaattcccc acccctctcc cgggcgga  
gg 180

gggcgggaag agcgcgtcct ggccaagccg agtagtgtct tccactcggt gcgtctct

ct 240

aggagccgcg cgggaaggat gctggtccgc aggggcgcgc gcgcagggcc caggatgc  
cg 300

cggggctgga ccgcgctttg cttgctgagt ttgctgcctt ctgggttcat gagtcttg  
ac 360

aacaacggta ctgctacccc agagttacct acccagggaa cattttcaaa tgtttcta  
ca 420

aatgtatcct accaagaaac tacaacacct agtacccttg gaagtaccag cctgcacc  
ct 480

gtgtctcaac atggcaatga ggccacaaca aacatcacag aaacgacagt caaattca  
ca 540

tctacctctg tgataacctc agtttatgga aacacaaact cttctgtcca gtcacaga  
cc 600

tctgtaatca gcacagtgtt caccacccca gccaacgttt caactccaga gacaacct  
tg 660

aagcctagcc tgtcaectgg aaatgtttca gacctttcaa ccactagcac tagccttg  
ca 720

acatctccca ctaaacccta tacatcatct tctcctatcc taagtacat caaggcag  
aa 780

atcaaagtgt caggcatcag agaagtgaag ttgactcagg gcactctgct ggagcaaa  
at 840

aagacctcca gctgtgcgga gtttaagaag gacaggggag agggcctggc ccgagtgc  
tg 900

tgtggggagg agcaggctga tgctgatgct ggggcccagg tatgtccct gtccttg  
cc 960

cagtctgagg tgaggcctca gtgtctactg ctggctcttg ccaacagaac agaaattt  
cc 1020

agcaaactcc aacttatgaa aaagcaccaa tctgacctga aaaagctggg gatcctag  
at 1080

ttcactgagc aagatgttgc aagccaccag agctattccc aaaagacct gattgcac  
tg 1140

gtcacctcgg gagccctgct ggctgtcttg ggcactactg gctatttct gatgaatc  
gc 1200

cgcagctgga gccccacagg agaaaggctg ggcgaagacc cttattacac ggaaaacg  
gt 1260

ggaggccagg gctatagctc aggacctggg acctccctg aggctcaggg aaaggcca  
gt 1320

gtgaaccgag gggctcagga aaacgggacc ggccaggcca cctccagaaa cggccatt  
ca 1380

gcaagacaac acgtggtggc tgataccgaa ttgtgactcg gctaggtggg gcaaggct  
gg 1440

gcagtgtccg agagagcacc cctctctgca tctgaccacg tgctaccccc atgctgga  
gg 1500

tgacatctct tacgccaac ccttccccac tgcacacacc tcagaggctg ttcttggg  
gc 1560

cctacacctt gaggaggggc aggtaaactc ctgtccttta cacattcggc tccctgga  
gc 1620

cagactctgg tcttcttttg gtaaacgtgt gacgggggaa agccaaggtc tggagaag  
ct 1680

cccaggaaca actgatggcc ttgcagcact cacacaggac ccccttcccc taccctc  
cc 1740

tctctgccgc aatacaggaa cccccagggg aaagatgagc ttttctaggc tacaattt  
tc 1800

tcccaggaag ctttgatttt taccgtttct tccctgtatt ttctttctct actttgag  
ga 1860

aaccaaagta accttttgca cctgctctct tgtaatgata tagccagaaa aacgtggt  
gc 1920

cttgaaccac ttccctcatc tctcctccaa gacactgtgg acttggtcac cagctcct  
cc 1980

cttgttctct aagttccact gagctccatg tgccccctct accatttgca gagtcctg  
ca 2040

cagttttctg gctggagcct agaacaggcc tcccaagttt taggacaaac agctcagt  
tc 2100

tagtctctct ggggccacac agaaactctt ttgggctct ttttctccc tctggatc  
aa 2160

agtaggcagg accatgggac caggtcttgg agctgagcct ctcacctgta ctcttccg  
aa 2220

aaatcctctt cctctgaggc tggatcctag ccttatcctc tgatctccat ggcttcct  
cc 2280

tcctcctgc cgactcctgg gttgagctgt tgcctcagtc ccccaacaga tgcttttc  
tg 2340

ttcttgctc cctcaccctg agccccttcc ttgctctgca ccccatatg gtcatagc  
cc 2400

agatcagctc ctaaccctta tcaccagctg cctcttctgt gggtgacca ggtccttg  
tt 2460

tgctgttgat ttctttccag aggggttgaa cagggatcct ggtttcaatg acggttgg  
aa 2520

atagaaattt ccagagaaga gagtattggg tagatatttt ttctgaatac aaagtgat  
gt 2580

gtttaatac tgcaattaaa gtgatactga aacac  
2615